Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience

BACKGROUND: Cyclin‐dependent kinases 4 and 6 inhibitors (CDK4/6i) have been shown to improve progression‐free survival (PFS) in patients with metastatic breast cancer (MBC) in randomized control trials. This study aimed to evaluate the efficacy and safety of CDK4/6i in patients with advanced breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Tzu‐Rong, Chen, Jia‐Hui, Wu, Ta‐Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599972/
https://www.ncbi.nlm.nih.gov/pubmed/37667421
http://dx.doi.org/10.1111/1759-7714.15090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599972/
https://www.ncbi.nlm.nih.gov/pubmed/37667421
http://dx.doi.org/10.1111/1759-7714.15090

Ejemplares similares